Drug discovery aims to find new molecules that can safely and effectively treat disease, and it combines biology, chemistry, computation and medicine.

The process usually starts by identifying a biological target, often a protein whose activity is linked to a disease. Researchers then look for “hits,” small molecules or biologics that interact with this target. Modern approaches use high throughput screening of large chemical libraries, structure based design guided by protein 3D structures, and virtual screening with computational models to prioritize candidates. Fragment based methods build potent drugs from very small chemical pieces that bind weakly but specifically.

Once hits are found, medicinal chemists optimize them into “lead” compounds by improving potency, selectivity and pharmacokinetic properties. They adjust features that affect absorption, distribution, metabolism and excretion while avoiding toxic effects. This involves iterative design, synthesis and testing supported by in vitro assays and sometimes advanced cell models or organoids.

Machine learning increasingly helps at each step. Algorithms predict protein structures, suggest new molecules, estimate binding affinity and forecast properties such as solubility or toxicity. Generative models can propose novel chemical structures, potentially expanding beyond known chemical space and reducing experimental workload.

Promising leads move into preclinical studies in cells and animals to evaluate efficacy and safety, followed by clinical trials in humans. Throughout, researchers must address challenges such as off target effects, drug resistance in pathogens or cancer cells, and limited translation from models to patients.

Overall, modern drug discovery is shifting toward more rational, data driven and AI assisted strategies, with the goal of making the process faster, cheaper and more successful.